Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_provenance.
- NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_assertion description "[Both infliximab (chimeric anti-tumor necrosis factor [TNF]-alpha antibody) and etanercept (p75 TNF-alpha receptor/immunoglobulin G fusion protein) are effective against rheumatoid arthritis, but only infliximab induces clinical remission in Crohn's disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_provenance.
- NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_assertion evidence source_evidence_literature NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_provenance.
- NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_assertion SIO_000772 15685549 NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_provenance.
- NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_assertion wasDerivedFrom befree-20140225 NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_provenance.
- NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_assertion wasGeneratedBy ECO_0000203 NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_provenance.
- befree-20140225 importedOn "2014-02-25" NP828667.RAt1ebd9CgHyYd2o8W7FXVk2_wPBTfWlSNuFwNZ0Tdu-E130_provenance.